PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.20 | -0.21 | 0.39 |
| FCF Yield | -66.68% | -38.04% | -18.09% | -4.60% |
| EV / EBITDA | -0.52 | -1.58 | -3.94 | -15.20 |
| Quality | ||||
| ROIC | -37.83% | -33.53% | -29.57% | -18.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.81 | 0.87 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 8.27% | 21.08% | -49.72% | -45.71% |
| Safety | ||||
| Net Debt / EBITDA | 0.54 | 0.31 | 1.23 | 2.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,099.07 | -939.94 | -1,682.37 | -908.65 |